Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-25.97M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.69 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -201.49% |
| Return on Assets (Trailing 12 Months) | -119.21% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.08 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.36 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.35 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-5.31 |
| Earnings per Share (Most Recent Fiscal Year) | $-87.27 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 1.80M |
| Free Float | 1.79M |
| Market Capitalization | $4.92M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 1.65 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 8.06% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |